Patent · US Active

CD3-binding molecules capable of binding to human and non-human CD3

US9587021B2 · kind B2 · utility

27Cited by
5References
24Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 16, 2012
Grant dateMar 7, 2017
Priority date—
Expiry dateFeb 25, 2034

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02E10/52
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

CD3-binding molecules capable of binding to human and non-human CD3, and in particular to such molecules that are cross-reactive with CD3 of a non-human mammal (e.g., a cynomolgus monkey) are presented. Uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other conditions are presented.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.